PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
8.54%
Cost growth of 8.54% while AVXL maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-83.05%
Gross profit decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A growth above 1.5x AVXL's 0.67%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.93%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine advantage.
8.54%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
7.52%
Similar EBITDA growth to AVXL's 8.61%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth below 50% of AVXL's 32.53%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while AVXL shows 12.85% growth. Joel Greenblatt would examine advantage.
7.01%
Pre-tax income growth below 50% of AVXL's 16.39%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while AVXL shows 232.91% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth below 50% of AVXL's 15.02%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth 50-75% of AVXL's 15.38%. Martin Whitman would scrutinize operations.
8.82%
Diluted EPS growth 50-75% of AVXL's 15.38%. Martin Whitman would scrutinize operations.
0.91%
Share count reduction exceeding 1.5x AVXL's 2.87%. David Dodd would verify capital allocation.
0.91%
Diluted share reduction exceeding 1.5x AVXL's 2.87%. David Dodd would verify capital allocation.